Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more

Register using your

BUSINESS OF BIOTECHNOLOGY back to topic

Q&A with CEO of BioSante Pharmaceuticals (NasdaqGM: BPAX) Following News of Positive LibiGel® Safety Data Review in Phase III Program

investorideas.com. Added by Dawn Van Zant on October 24, 2011

report

save

This article has:

Reactions to Q&A with CEO of BioSante Pharmaceuticals (NasdaqGM: BPAX) Following News of Positive LibiGel® Safety Data Review in Phase III Program

Date

Type Channel Author

Search Cancel